Business Wire

ClickHouse Strengthens Collaboration with Microsoft through Microsoft OneLake Integration for Seamless Data Interoperability

18.11.2025 21:00:00 CET | Business Wire | Press Release

Share

ClickHouse Inc., the company behind one of the world’s fastest and most popular real-time analytics databases, today announced the availability of a powerful new integration with Microsoft OneLake, the unified data lake of Microsoft Fabric.

This integration enables organizations to harness the scale, governance, and simplicity of OneLake with the speed and flexibility of ClickHouse for real-time, large-scale analytical workloads. Learn more in our technical post.

Expanding the ClickHouse-Microsoft collaboration

Following the general availability of ClickHouse Cloud on Microsoft Azure, recent performance enhancements of ClickHouse on Azure Blob Storage, and a steady series of new capabilities, this integration with Microsoft OneLake marks the latest milestone in ClickHouse’s growing collaboration with Microsoft.

This initiative reinforces ClickHouse’s commitment to deep interoperability across Microsoft’s data ecosystem. From Azure to Fabric, the goal is to enable real-time analytics within a unified platform for Microsoft customers.

Improved interoperability between ClickHouse and Microsoft OneLake

Organizations are increasingly unifying their data with a lakehouse architecture, a flexible foundation that supports best-of-breed tools across workloads, from large-scale analytics with ClickHouse to emerging GenAI and AI agent use cases and more. By storing data in open table formats such as Apache Iceberg or Delta Lake, teams ensure accessibility and interoperability across engines, including ClickHouse, so they can always use the right tool for the job.

The ClickHouse integration with OneLake Table APIs exposes Iceberg tables to ClickHouse, allowing users to directly access and analyze their data, facilitating federated and unified analytics across both ClickHouse and Fabric.

Facilitating real-time analytics with ClickHouse

A common challenge for databases is simplifying how data is ingested into the system itself. This new integration gives Fabric customers powerful new options to query critical data in low latency and high concurrency from OneLake with ClickHouse, enabling new workloads such as real-time analytics, operational dashboards, and agent-facing analytics.

“Microsoft OneLake is a very popular data lake solution among our users, and we’ve long wanted to provide a direct integration to enhance their experience, especially by simplifying data movement and analysis. With the introduction of Table APIs in OneLake, we were finally able to do just that. ClickHouse can now natively query data stored in OneLake, giving users seamless access to all their data in OneLake with zero friction,” said Alexey Milovidov, Co-Founder and CTO of ClickHouse.

“For data to be useful, it must be interoperable with a range of tools our customers use every day,” said Dipti Borkar, VP & GM for Microsoft OneLake and Fabric Ecosystem. “Customers can now use ClickHouse on data unified by Microsoft OneLake to deliver on some of the most data-intensive use cases, like real-time observability, cybersecurity & fraud detection and AI.”

About ClickHouse

ClickHouse is a fast, open-source columnar database management system built for real-time data processing and analytics at scale. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed and concurrency, making it ideal for applications that demand instant insight from massive volumes of data. As AI agents become increasingly embedded in software and are generating far more frequent and complex queries, ClickHouse brings a high-throughput, low-latency engine, purpose-built to meet this challenge. Trusted by leading companies like Sony, Tesla, Anthropic, Memorial Sloan Kettering, Lyft, and Instacart, ClickHouse helps teams unlock insights and drive smarter decisions with a scalable, efficient, and modern data platform. For more information, visit clickhouse.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251118733295/en/

Contacts

Tanya Bragin
VP, Product & Marketing
press@clickhouse.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye